Multiple Myeloma Study

Principal Investigator: R. Vinod Parameswaran, MD

Sub-Investigators: Kelly McCaul, MD; Mark Huber, MD; Amy Krie, MD; Michael Robinson, MD; Addison Tolentino, MD; Tammie Smart, CNP; Kristen Hurley, CNP

Study Coordinator: Erika Meyer, RN

Study Description: A Phase 1 Study of SGN-40 (Anti-hu-CD40 mAb), Lenalidomide (Revlimid®, cc-5013) and Dexamethasone in Patients with Multiple Myeloma

Overview: The purpose of this clinical research study is to determine the effectiveness and safety of an investigational medication when combined with lenalidomide and dexamethasone in treating patients with Multiple Myeloma.

Participants in this study will receive the investigational medication at no cost.

Inclusion Criteria:

• Males and females, age 18 and older
• Diagnosis of Multiple Myeloma
• Have received at least one prior systemic therapy other than single-agent corticosteroids

Exclusion Criteria:

• Women who are pregnant, breastfeeding or planning to become pregnant
• History of stroke, unstable angina or myocardial infarction within the past 6 months
• Have had an allogeneic stem cell transplant
• Positive HIV, hepatitis B or hepatitis C status

Contact: Erika Meyer, RN

Phone: (605) 322-3086

Email: erika.meyer@avera.org

Click here to learn more about the Avera Cancer Institute.